BiotechTube

Live attenuated Japanese encephalitis chimeric virus vaccine + Japanese encephalitis live attenuated vaccine (SA14 14 2 vaccine)

Phase 3Completed
1 views this week 0 watching⚡ Active
Interest: 40/100
40
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Japanese Encephalitis

Conditions

Japanese Encephalitis, Japanese Encephalitis Virus Disease

Trial Timeline

Jul 1, 2011 → Jun 1, 2013

NCT ID
NCT01396512

About Live attenuated Japanese encephalitis chimeric virus vaccine + Japanese encephalitis live attenuated vaccine (SA14 14 2 vaccine)

Live attenuated Japanese encephalitis chimeric virus vaccine + Japanese encephalitis live attenuated vaccine (SA14 14 2 vaccine) is a phase 3 stage product being developed by Sanofi for Japanese Encephalitis. The current trial status is completed. This product is registered under clinical trial identifier NCT01396512. Target conditions include Japanese Encephalitis, Japanese Encephalitis Virus Disease.

What happened to similar drugs?

3 of 20 similar drugs in Japanese Encephalitis were approved

Approved (3) Terminated (0) Active (17)
✅IMOJEV®: Live attenuated Japanese encephalitis chimeric virus vaccine + IMOJEV®: Live attenuated Japanese encephalitis chimeric virus vaccineSanofiApproved
✅IXIARO®- Japanese Encephalitis vaccineValneva SEApproved
✅IXIARO®Valneva SEApproved
🔄MEDI3250 + PlaceboAstraZenecaPhase 3
🔄MEDI3250AstraZenecaPhase 3
🔄ChimeriVax™-JE + JE-VAX®SanofiPhase 3
🔄IMOJEVSanofiPhase 3

Hype Score Breakdown

Clinical
17
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT01396512Phase 3Completed

Competing Products

20 competing products in Japanese Encephalitis

See all competitors
ProductCompanyStageHype Score
ASP3325 + PlaceboAstellas PharmaPhase 1
29
E6130 + PlaceboEisaiPhase 1
29
E2022 + E2022 + E2022 + E2022 + E2022EisaiPhase 1
29
AZD3293 + PlaceboAstraZenecaPhase 1
29
MEDI3250 + PlaceboAstraZenecaPhase 3
40
MEDI3250AstraZenecaPhase 3
40
Fostamatinib 100mg + Fostamatinib 200mgAstraZenecaPhase 1
29
NXL104 + CAZ104 + PlaceboPfizerPhase 1
29
CAIV-T + PlaceboPfizerPhase 1
29
ChimeriVax™-JE + JE-VAX®SanofiPhase 3
40
ChimeriVax™-JE + Japanese Encephalitis Inactivated Mouse Brain VaccineSanofiPhase 2
35
Live attenuated Japanese encephalitis virus + Live attenuated Japanese encephalitis virus + Live attenuated Japanese encephalitis virus + ChimeriVax™ diluent (Placebo)SanofiPhase 2
35
ChimeriVax™-JE vaccine + JE-VAX® vaccineSanofiPhase 2
35
IMOJEVSanofiPhase 3
40
Live attenuated Japanese encephalitis chimeric virus vaccine (IMOJEV®) + Live attenuated Japanese encephalitis chimeric virus vaccine (IMOJEV®) + Live attenuated Japanese encephalitis chimeric virus vaccine (IMOJEV®) + Live attenuated Japanese encephalitis chimeric virus vaccine (IMOJEV®)SanofiPhase 3
40
a live attenuated chimeric JE vaccineSanofiPre-clinical
26
Japanese encephalitis chimeric virus: Measles, mumps, and rubella live attenuated virus + Japanese encephalitis chimeric virus: Measles, mumps, and rubella live attenuated virus + Japanese encephalitis chimeric virus: Measles, mumps, and rubella live attenuated virusSanofiPhase 3
40
IMOJEV®: Live attenuated Japanese encephalitis chimeric virus vaccine + IMOJEV®: Live attenuated Japanese encephalitis chimeric virus vaccineSanofiApproved
43
JE-CV Vaccine + Varicella VaccineSanofiPhase 3
40
Live attenuated Japanese encephalitis virus; Yellow fever virus + Yellow fever virus; Live attenuated Japanese encephalitis virus + Live attenuated Japanese encephalitis virus; Yellow fever virus + Live attenuated Japanese encephalitis virus; Yellow fever virusSanofiPhase 2
35